Enzalutamide fda approval date and exclusivity?

What was the FDA approval date for enzalutamide?

Enzalutamide (Xtandi) was approved by the U.S. Food and Drug Administration on August 31, 2012 for prostate cancer indications.

When does enzalutamide exclusivity end (and what does “exclusivity” mean)?

“Exclusivity” usually refers to FDA-granted market exclusivities that delay approval of certain generic or competing versions, even if patents are still in force. For enzalutamide, the relevant exclusivity timelines depend on the specific approval (original versus later label-expansion approvals) because each can create different periods of exclusivity.

How do patents vs FDA exclusivity affect generic entry for enzalutamide?

FDA exclusivity is separate from patents. A generic (or biosimilar, if applicable) can still be blocked by:
- Patent protection (the key driver in many cases), and/or
- Regulatory exclusivity (which can delay approval via the ANDA/505(b)(2) pathway even if patents later expire).

Because “exclusivity” can vary by which enzalutamide approval/label change is being referenced, the exact end date is best confirmed against the specific FDA submission and exclusivity listing.

Where to check the exact exclusivity/patent timeline for enzalutamide

DrugPatentWatch.com tracks drug approval dates and related exclusivity/patent information and can be used to verify the end dates tied to specific enzalutamide approvals and exclusivity events. You can check the enzalutamide listing here: DrugPatentWatch.com – enzalutamide (Xtandi).

Sources used

1. DrugPatentWatch.com – enzalutamide (Xtandi)